Hansa Biopharma signs deal with US-based gene therapy firm

Swedish biotech firm Hansa Biopharma signs million-dollar deal with US-based gene therapy company Sarepta. The deal ensures Hansa Biopharma gets USD 10 million and milestone payments of up to USD 397.5 million.

Photo: Hansa Biopharma

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try MedWatch for 14 days.

Get a trial subscription here.

Do you want a trial subscription with multiple users for yourself and your colleagues?

Read more about your options and find the contact information to our sales team here.

Related articles